Virbac SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Virbac SA Issues FY 2013 Organic Growth and Operating Profitability Guidance; Proposes FY 2012 Dividend
Virbac SA announced that it expects 5 to 7% organic growth and a further 0.5 point improvement of operating profitability in fiscal year 2013. The Company also announced that a dividend of EUR 1.90 per share for fiscal year 2012, as compared to EUR 1.75 in fiscal year 2011, shall be proposed at the next Annual Shareholders Meeting and will be payable on June 26, 2013.
Latest Developments for Virbac SA
Latest Key Developments in Pharmaceuticals
- Eli Lilly and Co reaffirms FY 2014 earnings outlook; lowers high end of prior FY 2014 revenue outlook to a range in line with analysts' estimates
- Ablynx NV's anti-Il-6r nanobody partnered with AbbVie Inc demonstrates a bioavailability of more than 80 pct after subcutaneous injection
- Merro Pharmaceutical Co Ltd announces change of accounting policy
- Share this
- Digg this